Morgan Stanley Maintains Equal-Weight on Globus Medical, Lowers Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Drew Ranieri maintains an Equal-Weight rating on Globus Medical (NYSE:GMED) and lowers the price target from $64 to $60.
May 31, 2023 | 11:35 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley maintains an Equal-Weight rating on Globus Medical and lowers the price target from $64 to $60.
The news directly mentions Globus Medical (GMED) and the lowered price target by Morgan Stanley. However, the Equal-Weight rating remains unchanged, indicating a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100